Drug:
Reaction: DISEASE PROGRESSION
20250101 - 20251231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 25097807 |
IN |
62 | 2 |
Disease progression, |
||||
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, |
||||
| 202 | 25097826 |
PK |
47 | 2 |
Disease progression, |
||||
TRASTUZUMAB, |
||||
| 203 | 25098228 |
JP |
66 | 1 |
Disease progression, Lung opacity, Influenza, Bacteraemia, |
||||
BELUMOSUDIL, VORICONAZOLE, LETERMOVIR, |
||||
| 204 | 25098267 |
AU |
||
Disease progression, Drug ineffective, Drug intolerance, Therapeutic product effect incomplete, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, PREGABALIN, GABAPENTIN, IPILIMUMAB, MORPHINE, PEMETREXED, PEMETREXED DISODIUM, NIVOLUMAB, |
||||
| 205 | 25098459 |
AU |
||
Diffuse large B-cell lymphoma refractory, Disease progression, Drug ineffective, |
||||
RITUXIMAB, CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE, |
||||
| 206 | 25098568 |
GR |
||
Disease progression, |
||||
BEVACIZUMAB, LEUCOVORIN CALCIUM, FLUOROURACIL, IRINOTECAN HYDROCHLORIDE, AMOXICILLIN, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, |
||||
| 207 | 25098645 |
IQ |
58 | 2 |
Disease progression, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CISPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE, |
||||
| 208 | 25098724 |
US |
72 | 2 |
Hospitalisation, Dyspnoea, Decreased activity, Balance disorder, Nervousness, Weight increased, Asthenia, Decreased appetite, Oedema peripheral, Disease progression, |
||||
OSILODROSTAT, OSILODROSTAT, OSILODROSTAT, PIOGLITAZONE, ALPRAZOLAM, ATENOLOL, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, BUPROPION HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE, DULOXETIN HYDROCHLORIDE, DULOXETINE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, SEMAGLUTIDE, CLOPIDOGREL, SPIRONOLACTONE, INSULIN DEGLUDEC, |
||||
| 209 | 25098847 |
US |
||
Disease progression, |
||||
ACALABRUTINIB, |
||||
| 210 | 25098955 |
US |
1 | |
Neoplasm, Disease progression, Blood bilirubin increased, Off label use, |
||||
LENALIDOMIDE, LENALIDOMIDE, |
||||
| 211 | 25099160 |
US |
78 | 1 |
Drug ineffective, Disease progression, |
||||
OXALIPLATIN, FLUOROURACIL, |
||||
| 212 | 25099896 |
GB |
24 | 1 |
Post transplant lymphoproliferative disorder, Disease progression, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, AZATHIOPRINE, |
||||
| 213 | 25100137 |
US |
2 | |
Disease progression, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 214 | 25100678 |
US |
43 | 2 |
Disease progression, Drug ineffective, |
||||
ETOPOSIDE, ETOPOSIDE, DOXORUBICIN, DOXORUBICIN, CISPLATIN, CISPLATIN, MITOTANE, MITOTANE, |
||||
| 215 | 25100805 |
CN |
||
Disease progression, Device delivery system issue, Drug dose omission by device, |
||||
| 216 | 25100857 |
FR |
75 | 1 |
Fall, Disease progression, Device breakage, Freezing phenomenon, General physical health deterioration, |
||||
FOSCARBIDOPA/FOSLEVODOPA, |
||||
| 217 | 25101134 |
TR |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 218 | 25101349 |
TR |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 219 | 25101461 |
US |
43 | 2 |
Disease progression, |
||||
| 220 | 25101639 |
RU |
||
Disease progression, |
||||
VEMURAFENIB, COBIMETINIB, |
||||
| 221 | 25102065 |
DE |
80 | 2 |
Langerhans^ cell histiocytosis, Disease progression, Drug ineffective, |
||||
PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 222 | 25102109 |
TR |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 223 | 25104636 |
41 | 1 | |
Prostate cancer, Disease progression, |
||||
DAROLUTAMIDE, |
||||
| 224 | 25092343 |
CN |
2 | |
Disease progression, Drug resistance, |
||||
CARBOPLATIN, CAPECITABINE, DOXORUBICIN, PACLITAXEL, BEVACIZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PERTUZUMAB, VINORELBINE, TRASTUZUMAB, |
||||
| 225 | 25092352 |
US |
61 | 1 |
Treatment failure, Disease progression, Upper gastrointestinal haemorrhage, |
||||
BORTEZOMIB FOR INJECTION, BORTEZOMIB, DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, ETOPOSIDE, |
||||
| 226 | 25092354 |
RU |
14 | 1 |
Disease progression, Toxic epidermal necrolysis, |
||||
ALENDRONATE SODIUM, ALENDRONATE SODIUM TABLET, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, METHYLPREDNISOLONE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, TOPIRAMATE, TOPIRAMATE SPINKLE, TOPIRAMATE, TOPIRAMATE SPINKLE, URSODIOL, URSOSIOL, VALPROIC ACID, BENZOCAINE, TOPICAL ANESTHETIC, MAGNESIUM HYDROXIDE, |
||||
| 227 | 25092356 |
FR |
18 | 2 |
Disease progression, |
||||
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, |
||||
| 228 | 25092360 |
CN |
2 | |
Disease recurrence, Disease progression, Drug resistance, Metastasis, |
||||
CARBOPLATIN, CAPECITABINE, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, BEVACIZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PEMBROLIZUMAB, VINORELBINE, |
||||
| 229 | 25092398 |
IT |
65 | 2 |
Spontaneous haemorrhage, Disease progression, |
||||
OBINUTUZUMAB, OBINUTUZUMAB, ZANUBRUTINIB, BENDAMUSTINE HCL, |
||||
| 230 | 25092409 |
JP |
||
Disease progression, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, |
||||
| 231 | 25092439 |
JP |
55 | 1 |
Skin reaction, Diarrhoea, Vomiting, Metastases to adrenals, Disease progression, |
||||
DASATINIB, DASATINIB, SITAGLIPTIN, MIGLITOL, AZILSARTAN KAMEDOXOMIL, AMLODIPINE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, |
||||
| 232 | 25092440 |
ES |
82 | 2 |
Disease progression, |
||||
OXALIPLATIN, LEUCOVORIN CALCIUM, FLUOROURACIL, |
||||
| 233 | 25092545 |
US |
33 | 1 |
Disease progression, Drug ineffective for unapproved indication, Drug ineffective, |
||||
ETOPOSIDE, DOXORUBICIN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, IFOSFAMIDE, CARBOPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CLADRIBINE, CYTARABINE, MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE, |
||||
| 234 | 25092971 |
CH |
1 | |
Disease progression, |
||||
RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, |
||||
| 235 | 25093475 |
CZ |
||
Nephropathy toxic, Disease progression, Haematopoietic stem cell mobilisation, Peripheral blood stem cell apheresis, Night sweats, Pyrexia, Intentional product use issue, |
||||
RITUXIMAB, RITUXIMAB, DOXORUBICIN, DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, IFOSFAMIDE, IFOSFAMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CISPLATIN, CISPLATIN, CYTARABINE, CYTARABINE, PREDNISONE, PREDNISONE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, LORATADINE, LORATADINE ORAL, LORATADINE, LORATADINE ORAL, OXALIPLATIN, OXALIPLATIN, GENTAMICIN, GENTAMICIN SULFATE, GENTAMICIN, GENTAMICIN SULFATE, VINORELBINE, VINORELBINE, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, |
||||
| 236 | 25094124 |
GR |
45 | 2 |
Metastases to thyroid, Disease progression, |
||||
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, OXALIPLATIN, |
||||
| 237 | 25094197 |
AT |
2 | |
Pneumococcal sepsis, Chronic graft versus host disease oral, Chronic graft versus host disease in liver, Scleroderma-like reaction, Scleroderma, Dry eye, Disease progression, Infection, Rash maculo-papular, Infection, Dyspnoea, Dysphagia, Weight decreased, |
||||
CYCLOSPORINE, CYCLOSPORINE, CYCLOSPORINE, ABACAVIR SULFATE, ABACAVIR, LAMIVUDINE, LAMIVUDINE ORAL, RUXOLITINIB, |
||||
| 238 | 25094497 |
US |
61 | 2 |
Drug ineffective, Disease progression, |
||||
OXALIPLATIN, FLUOROURACIL, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CAPECITABINE, PACLITAXEL, |
||||
| 239 | 25094498 |
US |
62 | 1 |
Drug ineffective, Disease progression, Neuropathy peripheral, Diarrhoea, |
||||
OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, FLUOROURACIL, FLUOROURACIL, FLUOROURACIL, FLUOROURACIL, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 240 | 25094502 |
US |
78 | 1 |
Drug ineffective, Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, PEMBROLIZUMAB, |
||||
| 241 | 25094586 |
US |
||
Disease progression, Arthralgia, |
||||
OLAPARIB, |
||||
| 242 | 25094766 |
GB |
73 | 1 |
Disease progression, Endocarditis, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, RITUXIMAB, VINCRISTINE SULFATE, PREDNISONE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 243 | 25095080 |
US |
||
Disease progression, |
||||
OLAPARIB, |
||||
| 244 | 25095969 |
PL |
39 | 1 |
Neutropenia, Rash macular, Tumour lysis syndrome, COVID-19, Disease progression, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, OBINUTUZUMAB, RITUXIMAB, MOSUNETUZUMAB, MOSUNETUZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, CYTARABINE, CISPLATIN, |
||||
| 245 | 25096139 |
PK |
53 | 1 |
Disease progression, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, |
||||
| 246 | 25096240 |
TW |
1 | |
Disease progression, |
||||
| 247 | 25096445 |
CO |
52 | 2 |
Disease progression, Diarrhoea, Vomiting, Lung disorder, Discouragement, Depressed mood, |
||||
RIBOCICLIB, RIBOCICLIB, ABEMACICLIB, |
||||
| 248 | 25097022 |
US |
1 | |
Disease progression, |
||||
EDARAVONE, EDARAVONE, |
||||
| 249 | 25097023 |
US |
2 | |
Disease progression, |
||||
EDARAVONE, EDARAVONE, |
||||
| 250 | 25097024 |
US |
||
Disease progression, |
||||
EDARAVONE, EDARAVONE, |
||||
| 251 | 25099322 |
83 | 1 | |
Disease progression, Prostate cancer, |
||||
LEUPROLIDE ACETATE, |
||||
| 252 | 25086702 |
JP |
17 | 1 |
Drug ineffective, Disease progression, |
||||
ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, METHYLPREDNISOLONE, |
||||
| 253 | 25086772 |
US |
||
Disease progression, Encephalopathy, Hypotension, Blood lactic acid increased, Gastrointestinal haemorrhage, |
||||
DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCYCLINE HYCLATE, |
||||
| 254 | 25086984 |
LB |
||
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 255 | 25087113 |
KR |
||
Disease progression, |
||||
TISLELIZUMAB-JSGR, |
||||
| 256 | 25087348 |
FR |
37 | 2 |
Influenza, HCoV-OC43 infection, Drug ineffective, Disease progression, Off label use, |
||||
BENDAMUSTINE HCL, BENDAMUSTINE HCL, CYCLOSPORINE, CYCLOSPORINE, ELTROMBOPAG, RITUXIMAB, RITUXIMAB, AMOXICILLIN, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, ROMIPLOSTIM, LETERMOVIR, POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, |
||||
| 257 | 25087398 |
CO |
26 | 2 |
Death, Disease progression, |
||||
HEMIN, |
||||
| 258 | 25087538 |
IN |
86 | 1 |
Hiccups, Constipation, Disease progression, Blood alkaline phosphatase increased, Pain in extremity, Gastrointestinal disorder, Dysuria, Lower urinary tract symptoms, Decreased appetite, Abdominal distension, |
||||
ATEZOLIZUMAB, |
||||
| 259 | 25087577 |
PK |
70 | 2 |
Disease progression, Condition aggravated, |
||||
BEVACIZUMAB, |
||||
| 260 | 25087590 |
KE |
||
Disease progression, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, BEVACIZUMAB, |
||||
| 261 | 25087817 |
LB |
||
Disease progression, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, |
||||
| 262 | 25087883 |
US |
73 | 1 |
Disease progression, Drug ineffective for unapproved indication, |
||||
PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, ABIRATERONE ACETATE, ABIRATERONE, ABIRATERONE ACETATE, ABIRATERONE, |
||||
| 263 | 25087977 |
US |
56 | 1 |
Disease progression, Palmar-plantar erythrodysaesthesia syndrome, |
||||
RIPRETINIB, RIPRETINIB, |
||||
| 264 | 25088224 |
US |
48 | 1 |
Multiple organ dysfunction syndrome, Drug ineffective, Disease progression, |
||||
AMPHOTERICIN B, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, |
||||
| 265 | 25088332 |
IT |
13 | 1 |
Disease progression, Treatment failure, Off label use, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, METHYLPREDNISOLONE, CLOBAZAM, ETHOSUXIMIDE, |
||||
| 266 | 25088408 |
IN |
58 | 1 |
Drug ineffective, Disease progression, Drug intolerance, |
||||
OXALIPLATIN, OXALIPLATIN, CAPECITABINE, CAPECITABINE, |
||||
| 267 | 25088453 |
CH |
||
Disease progression, |
||||
RITUXIMAB, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, VINCRISTINE SULFATE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, BENDAMUSTINE HCL, RITUXIMAB, |
||||
| 268 | 25088535 |
PT |
66 | 2 |
Disease progression, Gastrointestinal toxicity, |
||||
FLUOROURACIL, OXALIPLATIN, |
||||
| 269 | 25088682 |
US |
||
Disease progression, |
||||
OLAPARIB, |
||||
| 270 | 25088866 |
US |
||
Tumour lysis syndrome, Disease progression, Hypercalcaemia, |
||||
TECLISTAMAB, |
||||
| 271 | 25088899 |
CH |
||
Disease progression, |
||||
RITUXIMAB, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, VINCRISTINE SULFATE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, |
||||
| 272 | 25088959 |
JP |
6 | 2 |
Disease progression, Metastases to meninges, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, CARBOPLATIN, PACLITAXEL, |
||||
| 273 | 25088973 |
CN |
54 | 1 |
Disease progression, |
||||
GLOFITAMAB, |
||||
| 274 | 25089292 |
PL |
73 | 2 |
Disease progression, Upper respiratory tract infection, Inflammatory marker increased, Pneumonia, Neutropenia, Chronic obstructive pulmonary disease, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, MOSUNETUZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, PREDNISONE, LENALIDOMIDE, DOXORUBICIN, |
||||
| 275 | 25089357 |
US |
1 | |
Disease progression, Drug ineffective for unapproved indication, |
||||
PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, SIPULEUCEL-T, ABIRATERONE ACETATE, ABIRATERONE, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 276 | 25089522 |
PK |
38 | 1 |
Disease progression, |
||||
BEVACIZUMAB, |
||||
| 277 | 25089545 |
US |
||
Disease progression, Off label use, |
||||
OCRELIZUMAB, |
||||
| 278 | 25089654 |
LB |
1 | |
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 279 | 25089695 |
US |
1 | |
Dupuytren^s contracture, Disease progression, Disease recurrence, |
||||
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, |
||||
| 280 | 25089715 |
IT |
83 | 1 |
COVID-19, Disease progression, |
||||
PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, |
||||
| 281 | 25090539 |
US |
1 | |
Acute hepatic failure, Respiratory failure, Renal failure, Disease progression, |
||||
TRIFLURIDINE AND TIPIRACIL, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, MORPHINE SULFATE, LISINOPRIL, LEVOTHYROXINE SODIUM, |
||||
| 282 | 25090641 |
JP |
1 | |
Disease progression, |
||||
DAROLUTAMIDE, |
||||
| 283 | 25090881 |
68 | 1 | |
Disease progression, |
||||
DAROLUTAMIDE, VITAMIN C, FERROUS SULFATE, |
||||
| 284 | 25091069 |
TR |
43 | 2 |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 285 | 25091237 |
CN |
2 | |
Disease progression, |
||||
GLOFITAMAB, |
||||
| 286 | 25081840 |
IN |
53 | 2 |
Disease progression, Drug ineffective, |
||||
CAPECITABINE, |
||||
| 287 | 25081887 |
PK |
79 | 1 |
Disease progression, |
||||
RITUXIMAB, |
||||
| 288 | 25081906 |
NG |
||
Disease progression, |
||||
ADO-TRASTUZUMAB EMTANSINE, |
||||
| 289 | 25082010 |
IT |
||
Death, Disease progression, Medication error, Pain, Weight decreased, Neoplasm recurrence, |
||||
DURVALUMAB, TREMELIMUMAB, CARBOPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 290 | 25082423 |
IN |
||
Disease progression, |
||||
PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, RITUXIMAB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, CYTARABINE, CYTARABINE, CYTARABINE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 291 | 25083784 |
CN |
64 | 1 |
Disease progression, Arrhythmia, Pneumonia, Platelet count decreased, Erysipelas, Off label use, |
||||
OBINUTUZUMAB, VENETOCLAX, VENETOCLAX, ZANUBRUTINIB, BORTEZOMIB FOR INJECTION, BORTEZOMIB, BORTEZOMIB FOR INJECTION, BORTEZOMIB, LENALIDOMIDE, RITUXIMAB, |
||||
| 292 | 25083969 |
JP |
61 | 1 |
Platelet count decreased, Metastases to spinal cord, Disease progression, |
||||
ATEZOLIZUMAB, CARBOPLATIN, ETOPOSIDE, |
||||
| 293 | 25084201 |
US |
42 | 1 |
Therapy partial responder, Drug ineffective, Disease progression, |
||||
PEMETREXED, PEMETREXED DISODIUM, DOCETAXEL, DOCETAXEL ANHYDROUS, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, RAMUCIRUMAB, CARBOPLATIN, PEMBROLIZUMAB, |
||||
| 294 | 25084220 |
US |
4 | |
Drug ineffective, Disease progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, FLUOROURACIL, FLUOROURACIL, FLUOROURACIL, PACLITAXEL, CISPLATIN, |
||||
| 295 | 25084436 |
US |
||
Disease progression, |
||||
CAPIVASERTIB, |
||||
| 296 | 25085015 |
ES |
57 | 2 |
Disease progression, |
||||
IBRUTINIB, |
||||
| 297 | 25085116 |
CN |
||
Disease progression, |
||||
DEGARELIX, |
||||
| 298 | 25085583 |
BR |
65 | |
Endocarditis bacterial, Mitral valve incompetence, Osteonecrosis, Toothache, Wisdom teeth removal, Pain in jaw, Swelling, Abscess drainage, Erythema, Post procedural infection, Disease progression, Tooth abscess, |
||||
FULVESTRANT, FULVESTRANT, ATENOLOL, CEPHALEXIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, PREDNISONE, |
||||
| 299 | 25085603 |
89 | ||
Disease progression, |
||||
| 300 | 25085980 |
TR |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28